GSK launches new specialist rare diseases R&D unit; names new president for GSK Japan

UK drugs giant GlaxoSmithKline revealed yesterday that it has formed a new standalone unit specializing in the development and commercialization of medicines for rare diseases and has recruited a new head for its Japanese business.

Over 5,500 rare diseases have been identified of which less than 10% are currently being treated, presenting a significant unmet medical need, noted GSK. Despite the rarity of each condition, the number of diseases means that between 6% and 8% of the population may be affected by a rare disease. Many are genetic in origin, start in childhood and cause lifelong debility and premature death.

Operating under a lean structure, Marc Dunoyer, GSK's president of Asia Pacific and chairman of Japan, will lead this new operation, working closely with Patrick Vallance, GSK's senior vice president of drug discovery. The new unit will seek to leverage existing capabilities and partnerships and establish further in-licensing opportunities.